AvenCell

Investment area

Venture Investments

Date of investment

October 2024

AvenCell was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics to create an offering that leverages switchable universal T-cell technology developed by the former Cellex subsidiary GEMoaB GmbH, with a license to Intellia’s proprietary CRISPR/Cas9-based allogeneic platform. The combined entity is the first of its kind to integrate a Switchable CAR-T with an off-the-shelf solution for applications across cancer and auto-immune indications, allowing for greater flexibility and a reduction in cycle times that will provide patients in need with advanced cell therapy treatments at significantly reduced costs.